• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search
Home » Our Therapy » Multi-drug Resistant Organisms

Multi-drug Resistant Organisms

Multi-drug resistant organisms (MDROs) are bacteria that have become resistant to certain antibiotics. Like Clostridium difficile (C. diff.) infection, vancomycin-resistant Enterococcus (VRE) is a challenging healthcare acquired infection. VRE is a well-known complication among critically ill and immune compromised patients and is associated with increased mortality, length of hospital stay and costs.1-3

Both VRE and C. diff. are found in the intestinal tract and share similar risk factors including antibiotic use, contact with the healthcare system, and severe underlying illness. VRE positive patients also have been shown to have a greater prevalence of co-infection with multi-drug resistant organisms.4

A secondary analysis of the PUNCH CD study found a high degree of VRE clearance concomitant with administration of RBX2660 for recurrent C. diff.5  More study is needed to confirm the hypothesis that a microbiota-based drug may provide a method of VRE clearance.

References

  1. Tavadze M, Rybicki L, Mossad S, et al. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogenic hematopoietic cell transplantation. Bone Marrow Transplantation. 2014;49:1310-16.
  2. Jung E, Byun S, Lee H, Moon SI, Lee H. Vancomycin-resistant Enterococcus colonization in the intensive care unit: Clinical outcomes and attributable costs of hospitalization. Am J Infect Control. 2014;42:1062-6.
  3. Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: Assessing attributable cost and length of stay. J Hosp Infect. 2013;85:54-9.
  4. Fujitani S, George WL, Morgan MA, Nichols S, Murthy AR. Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections. Am J Infect Control. 2011;39:188-93.
  5. Dubberke E, Jones C. Clearance of vancomycin-resistant Enterococcus concomitant with administration of a microbiota-based drug targeted at recurrent Clostridium difficile infection. Presented at ECCMID 2015. April 25-28, 2015, Copenhagen, Denmark.

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us